Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mito-TEMPO is a mitochondria-targeted superoxide dismutase mimetic. Mito-TEMPO scavenges superoxide and alkyl radicals and prevents mitochondrial oxidation, necrosis and apoptosis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 51.00 | |
10 mg | In stock | $ 89.00 | |
25 mg | In stock | $ 178.00 | |
50 mg | In stock | $ 343.00 | |
100 mg | In stock | $ 571.00 | |
500 mg | In stock | $ 1,220.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 58.00 |
Description | Mito-TEMPO is a mitochondria-targeted superoxide dismutase mimetic. Mito-TEMPO scavenges superoxide and alkyl radicals and prevents mitochondrial oxidation, necrosis and apoptosis. |
In vitro |
METHODS: Human neuroblastoma cells SH-SY5Y were treated with Mito-TEMPO (25-100 μM) for 24 h. Cell viability was detected using MTT assay. RESULTS: No cytotoxic effect was shown on the cells in the Mito-TEMPO-treated group, and a significant increase in cell viability was detected after Mito-TEMPO treatment. [1] METHODS: Normal rat proximal renal tubular epithelial cell line NRK-52E was pretreated with Mito-TEMPO (10 μM) for 1 h, then stimulated with oxalate (700 μM) for 1 h. The mitochondrial membrane potential was detected by using MMP assay kit (JC-1). RESULTS: The control cells showed bright red fluorescence. Compared with the control, oxalate treatment attenuated the red fluorescence, and these changes were reversed by pretreatment with Mito-TEMPO. The RESULTS suggest that oxalate induces mitochondrial dysfunction, and Mito-TEMPO can inhibit this effect. [2] |
In vivo |
METHODS: To investigate the protective effect against hepatotoxicity, APAP (300 mg/kg) was intraperitoneally injected into C57BL/6J mice, and Mito-TEMPO (20 mg/kg in saline) was injected intraperitoneally 1.5-3 h later. RESULTS: Mito-TEMPO had a protective effect on the late hepatotoxicity of APAP. [3] METHODS: To investigate the effects on coronary vasodilatation and endothelial SK channel activity, Mito-TEMPO (1 mg/kg in saline) was intraperitoneally injected into C57BL/6J mice with or without diabetes once daily for four weeks. RESULTS: After 4 weeks of treatment with Mito-TEMPO, diabetic mice showed significantly improved endothelium-dependent diastolic responses of coronary arteries to ADP or NS309 and endothelial SK channel currents compared to untreated diabetic mice. [4] |
Molecular Weight | 510.03 |
Formula | C29H35N2O2P.Cl |
CAS No. | 1334850-99-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 60 mg/mL (117.64 mM), Sonification is recommended.
DMSO: 125 mg/mL (245.08 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mito-TEMPO 1334850-99-5 Immunology/Inflammation Metabolism NF-Κb Reactive Oxygen Species Mitochondrial Metabolism inhibit MitoTEMPO Mito TEMPO Inhibitor inhibitor